Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Vascularized Composite Allotransplantation
NCT03241719Phase 1Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2017
- Primary completion
- Jul 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldesleukin in Allograft Rejection (AR), sponsored by Brigham and Women's Hospital. Primary endpoint: Number of regulatory T cells. Started Oct 2017; status: terminated.
02
Drugs
aldesleukin
03
Conditions
Allograft Rejection (AR)
Beyond the preview
Go deeper on NCT03241719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241719.